Orum Therapeutics

Orum Therapeutics Pioneers the Development of Tumor-Targeted Protein Degraders to Improve Cancer Treatment. The company's neoDegrader is a novel proprietary payload for targeted protein degradation, and its Antibody neoDegrader Conjugate (AnDC) platform generates first-in-class antibody-drug conjugates. The first therapeutic candidates from the AnDC platform are under development for the treatment of solid tumors and blood cancers.